Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Pyrroles
  • Quality of Life

abstract

  • Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.

publication date

  • September 22, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.13.5145

PubMed ID

  • 18669464

Additional Document Info

start page

  • 3763

end page

  • 9

volume

  • 26

number

  • 22